Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ADM Announces Personalized Nutrition Collaboration with Mayo Clinic

ADM

ADM Announces Personalized Nutrition Collaboration with Mayo Clinic

  • Collaboration with Mayo Clinic’s Center for Individualized Medicine will investigate novel microbial solutions for improving health, including body weight

Archer Daniels Midland Company (NYSE: ADM) today announced a collaboration with Mayo Clinic in personalized nutrition. The company will work with Mayo’s Microbiome Program, led by Dr. Heidi Nelson, to investigate microbial solutions to improve health and wellness, initially focusing on the maintenance of healthy body weight.

“We are pleased to enter into this cutting-edge collaboration with Mayo Clinic to study the association of specific probiotics, prebiotics, and other nutrients with body weight,” said Vikram Luthar, ADM’s president, Bioactives. “Personalized nutrition is an important growth platform for ADM. Earlier this year, we acquired Biopolis, a leading player in health-promoting microbial technology. Now, by working with Mayo Clinic, we are further expanding our capabilities to develop personalized nutrition solutions to improve health and wellness, and bring these beneficial solutions directly to consumers.”

The goal of the collaboration is to develop a personalized nutrition model that predicts the effects of probiotics, prebiotics and other metabolites, as well as other nutrients in microbiome shifts, for improving individual health. In the initial phase, ADM and Mayo Clinic will work to design a computational method for testing probiotics, metabolites, and other intervention strategies that promote the growth of gut microbes linked to healthy body weight. Additional projects are planned to leverage both organizations’ strengths. Mayo Clinic will provide data analysis, modeling and gut microbiome expertise. ADM will bring expertise in food ingredients, strain development and genomics, as well as commercialization capabilities.

About ADM

For more than a century, the people of Archer Daniels Midland Company (NYSE: ADM) have transformed crops into products that serve the vital needs of a growing world. Today, we’re one of the world’s largest agricultural processors and food ingredient providers, with approximately 32,000 employees serving customers in more than 160 countries. With a global value chain that includes approximately 500 crop procurement locations, 250 ingredient manufacturing facilities, 38 innovation centers and the world’s premier crop transportation network, we connect the harvest to the home, making products for food, animal feed, industrial and energy uses. Learn more at www.adm.com.

Archer Daniels Midland Company
Media Relations
Jackie Anderson
media@adm.com
312-634-8484



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today